{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:59:21Z","timestamp":1793411961502,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PharmaEssentia Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To verify the clinical benefit of ropeginterferon alfa-2b (ropegIFN) and evaluate its cost-effectiveness compared with hydroxycarbamide or ruxolitinib for patients with polycythemia vera (PV) under the National Health Insurance (NHI) system in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The cost-effectiveness of ropegIFN compared with hydroxycarbamide or ruxolitinib was evaluated for patients with PV requiring cytoreductive therapy (without prior cytoreductive therapy) and resistant or intolerant to hydroxycarbamide. According to previous reports, patients with PV who achieve a molecular response with a\n                      <jats:italic>JAK<\/jats:italic>\n                      2V617F allele burden\u2009&lt;\u200910% tend to maintain hematologic responses even after discontinuing interferon treatment. Therefore, in these analyses, patients who achieved a molecular response with\n                      <jats:italic>JAK<\/jats:italic>\n                      2V617F burden\u2009&lt;\u200910% discontinued ropegIFN treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with hydroxycarbamide, ropegIFN yielded an incremental effectiveness of 0.440 quality-adjusted life years (QALYs), indicating a higher QALY gain. The incremental costs were 128,001,730 yen, and the incremental cost-effectiveness ratio (ICER) was 291,092,030 yen\/QALY. Compared with ruxolitinib, the incremental effectiveness of ropegIFN was 1.278 QALYs, while the total costs were reduced by 18,025,182 yen, which resulted in a dominant ICER.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that ropegIFN may be cost-effective compared with ruxolitinib in patients with PV who are resistant or intolerant to hydroxycarbamide under the NHI system in Japan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12185-025-04136-4","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:10:26Z","timestamp":1766581826000},"page":"556-569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan"],"prefix":"10.1007","volume":"123","author":[{"given":"Hiroki","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Igari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"4136_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3390\/genes13040637","volume":"13","author":"M Regimbeau","year":"2022","unstructured":"Regimbeau M, Mary R, Hermetet F, Girodon F. Genetic background of polycythemia vera. Genes (Basel). 2022;13:637.","journal-title":"Genes (Basel)"},{"key":"4136_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1465\u201387.","journal-title":"Am J Hematol"},{"key":"4136_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12185-018-2428-0","volume":"107","author":"A Kamiunten","year":"2018","unstructured":"Kamiunten A, Shide K, Kameda T, Sekine M, Kubuki Y, Ito M, et al. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan. Int J Hematol. 2018;107:681\u20138.","journal-title":"Int J Hematol"},{"key":"4136_CR4","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874\u201381.","journal-title":"Leukemia"},{"key":"4136_CR5","unstructured":"The Japanese Society of Hematology. JSH practical guidelines for hematological malignancies Version 3.1. 2024. Available from: http:\/\/www.jshem.or.jp\/gui-hemali\/table.html. Accessed 1 Mar 2025."},{"issue":"1","key":"4136_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12185-024-03865-2","volume":"121","author":"N Takahashi","year":"2025","unstructured":"Takahashi N, Takenaka K, Iriyama N, et al. JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2025;121(1):5\u201338.","journal-title":"Int J Hematol"},{"key":"4136_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Myeloproliferative Neoplasms. Version 2.2025."},{"issue":"3","key":"4136_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):196\u2013208.","journal-title":"Lancet Haematol"},{"issue":"10","key":"4136_CR9","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","volume":"37","author":"H Gisslinger","year":"2023","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia. 2023;37(10):2129\u201332.","journal-title":"Leukemia"},{"issue":"5","key":"4136_CR10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia. 2022;36(5):1408\u201311.","journal-title":"Leukemia"},{"issue":"6","key":"4136_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12185-024-03846-5","volume":"120","author":"K Kirito","year":"2024","unstructured":"Kirito K, Sugimoto Y, Gotoh A, Takenaka K, Ichii M, Inano T, et al. Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera. Int J Hematol. 2024;120(6):675\u201383.","journal-title":"Int J Hematol"},{"issue":"3","key":"4136_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S2352-3026(20)30373-2","volume":"8","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):175\u201384.","journal-title":"Lancet Haematol"},{"issue":"2","key":"4136_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jaad.2021.10.004","volume":"86","author":"JQ Lin","year":"2022","unstructured":"Lin JQ, Li SQ, Li S, Kiamanesh EF, Aasi SZ, Kwong BY, et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol. 2022;86(2):339\u201344.","journal-title":"J Am Acad Dermatol"},{"key":"4136_CR14","unstructured":"Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health. Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council 3rd edition. 2022. Available from: https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_ja.pdf. Accessed 1 Mar 2025."},{"key":"4136_CR15","unstructured":"Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare. Full Scale Introduction of Cost-Effectiveness Evaluations in Japan. 2019. Available from: https:\/\/c2h.niph.go.jp\/tools\/system\/overview_en.pdf. Accessed 1 Mar 2025."},{"issue":"4","key":"4136_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9(4):301\u201311.","journal-title":"Lancet Haematol"},{"issue":"1","key":"4136_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/16078454.2021.1967256","volume":"26","author":"Q Luo","year":"2021","unstructured":"Luo Q, Xiao Z, Peng L. Effects of ruxolitinib on infection in patients with myeloproliferative neoplasm: a meta-analysis. Hematology. 2021;26(1):663\u20139.","journal-title":"Hematology"},{"issue":"5","key":"4136_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1532\/IJH97.06009","volume":"83","author":"K Dan","year":"2006","unstructured":"Dan K, Yamada T, Kimura Y, Usui N, Okamoto S, Sugihara T, et al. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol. 2006;83(5):443\u20139.","journal-title":"Int J Hematol"},{"issue":"7","key":"4136_CR19","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","volume":"105","author":"G Finazzi","year":"2005","unstructured":"Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664\u201370.","journal-title":"Blood"},{"issue":"2","key":"4136_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","volume":"136","author":"M Di Nisio","year":"2007","unstructured":"Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136(2):249\u201359.","journal-title":"Br J Haematol"},{"issue":"7","key":"4136_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3324\/haematol.2016.143644","volume":"101","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016;101(7):821\u20139.","journal-title":"Haematologica"},{"issue":"2","key":"4136_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41375-021-01447-3","volume":"36","author":"G Abu-Zeinah","year":"2022","unstructured":"Abu-Zeinah G, Silver RT, Abu-Zeinah K, Scandura JM. Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia. 2022;36(2):569\u201372.","journal-title":"Leukemia"},{"key":"4136_CR23","unstructured":"Ministry of Health, Labour and Welfare. Overview of abridged life tables for 2023. Available from: https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/life\/life23\/. Accessed 1 Mar 2025."},{"key":"4136_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. London: Oxford University Press; 2006."},{"issue":"5","key":"4136_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70137","volume":"9","author":"JJ Kiladjian","year":"2025","unstructured":"Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea\/best available therapy (PROUD-PV\/CONTINUATION-PV). Hemasphere. 2025;9(5):e70137.","journal-title":"Hemasphere"},{"issue":"9","key":"4136_CR26","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0066","volume":"12","author":"AT Gerds","year":"2023","unstructured":"Gerds AT, Castro C, Snopek F, Flynn MM, Ellis AG, Manning M, et al. Cost\u2013effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera. J Comp Eff Res. 2023;12(9):e230066.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"4136_CR27","first-page":"219","volume":"104","author":"E Walter","year":"2025","unstructured":"Walter E, Torelli F, Barbui T. Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system. Ann Hematol. 2025;104(1):219\u201329.","journal-title":"Ann Hematol"},{"issue":"1","key":"4136_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41408-020-00392-1","volume":"11","author":"F Palandri","year":"2021","unstructured":"Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, et al. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J. 2021;11(1):4.","journal-title":"Blood Cancer J"},{"issue":"2","key":"4136_CR29","first-page":"199","volume":"4","author":"RJ van Rensburg","year":"2023","unstructured":"van Rensburg RJ, Hale S, Calara A, Dabb K, Dandamudi U, Desai P. Rapid hepatomegaly from ruxolitinib discontinuation syndrome. HCA Healthc J Med. 2023;4(2):199\u2013204.","journal-title":"HCA Healthc J Med"},{"issue":"3","key":"4136_CR30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s12185-025-04008-x","volume":"122","author":"S Shirane","year":"2025","unstructured":"Shirane S, Inano T, Fukuda Y, Ochiai T, Midorigawa N, Morishita S, et al. Ropeginterferon-\u03b12b discontinuation after long-term exposure: four cases from a single institution. Int J Hematol. 2025;122(3):458\u201361.","journal-title":"Int J Hematol"},{"issue":"11","key":"4136_CR31","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s00277-019-03793-w","volume":"98","author":"S Parasuraman","year":"2019","unstructured":"Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O, et al. Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data. Ann Hematol. 2019;98(11):2533\u20139.","journal-title":"Ann Hematol"},{"issue":"10","key":"4136_CR32","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/s41440-022-00952-x","volume":"45","author":"A Nomura","year":"2022","unstructured":"Nomura A, Tanigawa T, Kario K, Igarashi A. Cost-effectiveness of digital therapeutics for essential hypertension. Hypertens Res. 2022;45(10):1538\u201348.","journal-title":"Hypertens Res"},{"issue":"12","key":"4136_CR33","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1016\/j.clinthera.2015.10.007","volume":"37","author":"I Kamae","year":"2015","unstructured":"Kamae I, Hashimoto Y, Koretsune Y, Tanahashi N, Murata T, Phatak H, et al. Cost-effectiveness analysis of apixaban against warfarin for stroke prevention in patients with nonvalvular atrial fibrillation in Japan. Clin Ther. 2015;37(12):2837\u201351.","journal-title":"Clin Ther"},{"issue":"1","key":"4136_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.36469\/jheor.2020.13083","volume":"7","author":"J Hjelmgren","year":"2020","unstructured":"Hjelmgren J, Nilsson K, Birgeg\u00e5rd G. JAK2 V617F as a marker for long-term disease progression and mortality in polycythemia vera and its role in economic modeling. J Health Econ Outcomes Res. 2020;7(1):61\u201370.","journal-title":"J Health Econ Outcomes Res"},{"key":"4136_CR35","unstructured":"National Cancer Center. Cancer Information Service. Available from: https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/13_skin.html. Accessed 1 Mar 2025."},{"issue":"8","key":"4136_CR36","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jval.2021.03.010","volume":"24","author":"T Shiroiwa","year":"2021","unstructured":"Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021;24(8):1193\u2013202.","journal-title":"Value Health"},{"issue":"6","key":"4136_CR37","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0272989X11401031","volume":"31","author":"PW Sullivan","year":"2011","unstructured":"Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800\u20134.","journal-title":"Med Decis Making"},{"issue":"2","key":"4136_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13555-019-0291-4","volume":"9","author":"M Shiragami","year":"2019","unstructured":"Shiragami M, Mizukami A, Kaise T, Curran D, Van Oorschot D, Bracke B, et al. Cost-effectiveness of the adjuvant recombinant zoster vaccine in Japanese adults aged 65 years and older. Dermatol Ther (Heidelb). 2019;9(2):281\u201397.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"4136_CR39","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.clinthera.2019.07.016","volume":"41","author":"K Kaku","year":"2019","unstructured":"Kaku K, Haneda M, Sakamaki H, Yasui A, Murata T, Ustyugova A, et al. Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial. Clin Ther. 2019;41(10):2021\u201340.","journal-title":"Clin Ther"},{"issue":"1","key":"4136_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13555-018-0268-8","volume":"9","author":"S Imafuku","year":"2019","unstructured":"Imafuku S, Matsuki T, Mizukami A, Goto Y, de Souza S, J\u00e9gou C, et al. Burden of herpes zoster in the Japanese population with immunocompromised\/chronic disease conditions: results from a cohort study claims database from 2005\u20132014. Dermatol Ther (Heidelb). 2019;9(1):117\u201333.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04136-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04136-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04136-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:56:34Z","timestamp":1776254194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04136-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4136"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04136-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hiroki Yamaguchi received consulting fees from Nippon Shinyaku, AbbVie, PharmaEssentia, Sumitomo Pharma, Novartis Pharma, Daiichi-Sankyo; payment\/honoraria from Nippon Shinyaku, Sanofi, PharmaEssentia, Janssen Pharmaceutical, Novartis Pharma, Kyowa Kirin, Daiichi-Sankyo, Alexion Pharma, AbbVie, AstraZeneca, Astellas Pharma, Shionogi Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Genmab; medical writing support from PharmaEssentia Japan. Yuka Sugimoto is editor of International Journal of Hematology and received research funding from PharmaEssentia, Toyo Kohan, Incyte Biosciences Japan, MSD, Sumitomo Pharma, Sobi Japan; payment\/honoraria from Novartis Pharma, PharmaEssentia Japan, GlaxoSmithKline; medical writing support from PharmaEssentia Japan. Akihiko Gotoh received research funding from Asahi Kasei, Taiho Pharmaceutical, Otsuka Pharmaceutical, Kyowa Kirin, Chugai Pharmaceutical; consulting fees from PharmaEssentia Japan, Chugai Pharmaceutical, Alexion Pharma; honoraria from Novartis Pharma, Alexion Pharma, Asahi Kasei, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Nippon Shinyaku, Chugai Pharmaceutical, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, Daiichi-Sankyo, GlaxoSmithKline, Kyowa Kirin, Janssen Pharmaceutical, Pfizer Japan, Sanofi; data safety monitoring board\/advisory board fees from PharmaEssentia Japan, Chugai Pharmaceutical, Alexion Pharma; medical writing support from PharmaEssentia Japan. Shuichi Ota received payment\/honoraria from Novartis Pharma, Bristol Myers Squibb, Takeda Pharmaceutical, Janssen Pharmaceutical, AstraZeneca, Amgen, AbbVie, Sanofi, PharmaEssentia; medical writing support from PharmaEssentia Japan. Norio Komatsu is a board member of PharmaEssentia Japan; received medical writing support from PharmaEssentia Japan. Keita Kirito received payment\/honoraria from PharmaEssentia Japan, GlaxoSmithKline, Novartis Pharma; medical writing support from PharmaEssentia Japan. Hiromi Igari is an employee of PharmaEssentia Japan. Tatsunori Murata and Keigo Hanada are employees of CRECON Medical Assessment Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}